Mangoceuticals, Inc. engages in developing, marketing, and selling men's wellness products and services via a telemedicine platform. The company was founded on October 7, 2021 and is headquartered in Dallas, TX.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
• Eli Lilly has filed lawsuits against MangoRx and two other companies for allegedly selling unauthorized tirzepatide products, raising serious patient safety concerns. • MangoRx strongly refutes Eli Lilly's claims regarding their weight loss product Trim, which contains a compounded version of tirzepatide, and plans to vigorously defend against the allegations. • The legal action comes amid regulatory complexity, as FDA recently allowed pharmacists to continue making compounded versions of tirzepatide while reconsidering its removal from the shortage list.
- MangoRx has introduced TRIM, an oral dissolvable Tirzepatide tablet, priced at $399 per month, offering a convenient alternative to injectable weight loss therapies. - Clinical trials demonstrated that Tirzepatide can achieve significant weight loss, with participants experiencing up to 20% reduction in 72 weeks and 25% in 88 weeks. - The launch positions MangoRx to capitalize on the expanding GLP-1 market, projected to grow to $157.5 billion by 2035, driven by the obesity treatment segment. - MangoRx now provides both Tirzepatide (TRIM) and Semaglutide (SLIM) options via its telemedicine platform, enhancing access to advanced weight management solutions.
